Phase II Trial: uPAR-PET/MR in Patients With Newly Diagnosed Prostate Cancer; Non-invasive Characterization of Tumor Aggressiveness
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Gallium-68 NOTA AE105 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- 11 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 10 Sep 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Oct 2019.
- 25 Mar 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jul 2019.